BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 19010910)

  • 1. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
    Link PA; Baer MR; James SR; Jones DA; Karpf AR
    Cancer Res; 2008 Nov; 68(22):9358-66. PubMed ID: 19010910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia.
    Schmelz K; Wagner M; Dörken B; Tamm I
    Int J Cancer; 2005 May; 114(5):683-95. PubMed ID: 15609309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2'deoxycytidine (decitabine) are differentially regulated by cell cycle progression.
    Al-Salihi M; Yu M; Burnett DM; Alexander A; Samlowski WE; Fitzpatrick FA
    Epigenetics; 2011 Aug; 6(8):1021-8. PubMed ID: 21725200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consequences of combining siRNA-mediated DNA methyltransferase 1 depletion with 5-aza-2'-deoxycytidine in human leukemic KG1 cells.
    Vispé S; Deroide A; Davoine E; Desjobert C; Lestienne F; Fournier L; Novosad N; Bréand S; Besse J; Busato F; Tost J; De Vries L; Cussac D; Riond J; Arimondo PB
    Oncotarget; 2015 Jun; 6(17):15265-82. PubMed ID: 25948775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical development of demethylating agents in hematology.
    Navada SC; Steinmann J; Lübbert M; Silverman LR
    J Clin Invest; 2014 Jan; 124(1):40-6. PubMed ID: 24382388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes.
    Fandy TE; Jiemjit A; Thakar M; Rhoden P; Suarez L; Gore SD
    Clin Cancer Res; 2014 Mar; 20(5):1249-58. PubMed ID: 24423613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.
    Flotho C; Claus R; Batz C; Schneider M; Sandrock I; Ihde S; Plass C; Niemeyer CM; Lübbert M
    Leukemia; 2009 Jun; 23(6):1019-28. PubMed ID: 19194470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells.
    Tsujioka T; Yokoi A; Itano Y; Takahashi K; Ouchida M; Okamoto S; Kondo T; Suemori S; Tohyama Y; Tohyama K
    Sci Rep; 2015 Nov; 5():16709. PubMed ID: 26577244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML.
    Lund K; Cole JJ; VanderKraats ND; McBryan T; Pchelintsev NA; Clark W; Copland M; Edwards JR; Adams PD
    Genome Biol; 2014 Aug; 15(8):406. PubMed ID: 25315154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine.
    Karpf AR; Moore BC; Ririe TO; Jones DA
    Mol Pharmacol; 2001 Apr; 59(4):751-7. PubMed ID: 11259619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma.
    Rubinstein JC; Tran N; Ma S; Halaban R; Krauthammer M
    BMC Med Genomics; 2010 Feb; 3():4. PubMed ID: 20144234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.
    Yan P; Frankhouser D; Murphy M; Tam HH; Rodriguez B; Curfman J; Trimarchi M; Geyer S; Wu YZ; Whitman SP; Metzeler K; Walker A; Klisovic R; Jacob S; Grever MR; Byrd JC; Bloomfield CD; Garzon R; Blum W; Caligiuri MA; Bundschuh R; Marcucci G
    Blood; 2012 Sep; 120(12):2466-74. PubMed ID: 22786882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage.
    Tanaka H; Arakawa H; Yamaguchi T; Shiraishi K; Fukuda S; Matsui K; Takei Y; Nakamura Y
    Nature; 2000 Mar; 404(6773):42-9. PubMed ID: 10716435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor.
    Gray SG; Baird AM; O'Kelly F; Nikolaidis G; Almgren M; Meunier A; Dockry E; Hollywood D; Ekström TJ; Perry AS; O'Byrne KJ
    Int J Mol Med; 2012 Dec; 30(6):1505-11. PubMed ID: 23007409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cancer‑testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo.
    Zhou J; Li Y; Yao Y; Wang L; Gao L; Gao X; Luo X; Li J; Jiang M; Zhou M; Wang L; Yu L
    Mol Med Rep; 2013 Nov; 8(5):1549-55. PubMed ID: 24002123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells.
    Shin DY; Sung Kang H; Kim GY; Kim WJ; Yoo YH; Choi YH
    Biomed Pharmacother; 2013 May; 67(4):305-11. PubMed ID: 23582784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic evaluation of decitabine for the treatment of leukemia.
    Bryan J; Kantarjian H; Garcia-Manero G; Jabbour E
    Expert Opin Drug Metab Toxicol; 2011 May; 7(5):661-72. PubMed ID: 21500965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergism between clofarabine and decitabine through p53R2: a pharmacodynamic drug-drug interaction modeling.
    Thudium KE; Ghoshal S; Fetterly GJ; Haese JP; Karpf AR; Wetzler M
    Leuk Res; 2012 Nov; 36(11):1410-6. PubMed ID: 22884950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.